Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Context TherapeuticsCNTX +1.42%24 Return-on-Tangible-Equity is -61.64% as of Mar. 2026. GuruFocus rates CNTX with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 1,198 Biotechnology companies, Context Therapeutics ranks worse than 57.93% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Context Therapeutics's annualized net income for the quarter that ended in Mar. 2026 was $-34.72 Mil. Context Therapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $56.34 Mil. Therefore, Context Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -61.64%.
The historical rank and industry rank for Context Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
CNTX'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -102.79 Med: -49.89 Max: -35.74
Current: -55.97
During the past 7 years, Context Therapeutics's highest Return-on-Tangible-Equity was -35.74%. The lowest was -102.79%. And the median was -49.89%.
CNTX's Return-on-Tangible-Equity is ranked worse than 57.93% of 1198
companies
in the Biotechnology industry
Industry Median: -42.305
vs CNTX: -55.97
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Context Therapeutics Return-on-Tangible-Equity Related Terms
Context Therapeutics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Context Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNTX vs INKT, XLO, BOLD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Context Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Context Therapeutics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Context Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Context Therapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -61.64% mean?
Context Therapeutics (CNTX) has a Return-on-Tangible-Equity of -61.64% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Context Therapeutics and its competitors. According to the industry distribution chart, Context Therapeutics ranks #694 out of 1198 companies in the Biotechnology industry, placing it in the top 57.9%.
Is Context Therapeutics' Return-on-Tangible-Equity too high?
Context Therapeutics' current Return-on-Tangible-Equity is -61.64%. Based on the distribution chart, Context Therapeutics ranks #694 out of 1198 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Context Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Context Therapeutics' Return-on-Tangible-Equity compare to INKT and XLO?
According to the Biotechnology industry distribution chart, Context Therapeutics ranks #694 out of 1198 companies for Return-on-Tangible-Equity. This places Context Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Context Therapeutics and its competitors. Context Therapeutics's current Return-on-Tangible-Equity is -61.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Context Therapeutics stock overvalued right now?
Context Therapeutics (CNTX) has a current Return-on-Tangible-Equity of -61.64%. The current Return-on-Tangible-Equity is -61.64%. Context Therapeutics' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Context Therapeutics (CNTX), the current Return-on-Tangible-Equity is -61.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
24GF Score
Get the complete analysis for CNTX
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNTX has been successfully added to your 
